Published evidence for association between increased CAR T-cell expansion and clinical outcomes
| Study . | Clinical setting . | Patients with CAR T-cell expansion data . | CAR T-cell quantification assay . | Association with neurotoxicity . | Association with CRS . | Association with response to treatment . |
|---|---|---|---|---|---|---|
| Hamilton et al1 | Standard of care | Axi-cel, n = 124 (LBCL) and n = 19 (FL); brexu-cel, n = 17 (MCL) | Flow cytometry | Yes, with grade ≥3 ICANS | Yes, with grade ≥2 CRS | Not with PFS or with ongoing response |
| Wang et al2 | ZUMA-2 | Brexu-cel, n = 67 (MCL) | qPCR | Yes, with grade ≥3 NE | Yes, with grade ≥3 CRS | Yes, with ORR and with ongoing response |
| Jacobson et al5 | ZUMA-5 | Axi-cel, n = 124 (FL) and n = 24 (MZL) | qPCR | Yes, with grade ≥3 NE in FL | Yes, with grade ≥3 CRS in FL | Yes, with ongoing response in FL |
| Neelapu et al6 | ZUMA-1 | Axi-cel, n = 101 (LBCL) | qPCR | Yes, with grade ≥3 NE | Not with grade ≥3 CRS | Yes, with ORR and with ongoing response |
| Abramson et al7 | TRANSCEND NHL 001 | Liso-cel, n = 245 (LBCL) | qPCR | Yes, with grade ≥3 NE | Yes, with any grade CRS | Yes, with ORR |
| Filosto et al8 | ZUMA-7 | Axi-cel, n = 162 (LBCL) | qPCR | Yes, with grade ≥3 NE | Yes, with grade ≥3 CRS | Yes, with ORR but not with ongoing response |
| Good et al9 | Standard of care | Axi-cel, n = 32 (LBCL) | Flow cytometry and qPCR | Yes, with grade ≥2 ICANS | Yes, with grade 2 CRS | Not with ORR or with ongoing response |
| Blumenberg et al10 | Standard of care | Axi-cel, n = 60 (LBCL); tisa-cel, n = 58 (LBCL) | Flow cytometry | Not assessed | Not assessed | Yes, with PFS and with OS |
| Study . | Clinical setting . | Patients with CAR T-cell expansion data . | CAR T-cell quantification assay . | Association with neurotoxicity . | Association with CRS . | Association with response to treatment . |
|---|---|---|---|---|---|---|
| Hamilton et al1 | Standard of care | Axi-cel, n = 124 (LBCL) and n = 19 (FL); brexu-cel, n = 17 (MCL) | Flow cytometry | Yes, with grade ≥3 ICANS | Yes, with grade ≥2 CRS | Not with PFS or with ongoing response |
| Wang et al2 | ZUMA-2 | Brexu-cel, n = 67 (MCL) | qPCR | Yes, with grade ≥3 NE | Yes, with grade ≥3 CRS | Yes, with ORR and with ongoing response |
| Jacobson et al5 | ZUMA-5 | Axi-cel, n = 124 (FL) and n = 24 (MZL) | qPCR | Yes, with grade ≥3 NE in FL | Yes, with grade ≥3 CRS in FL | Yes, with ongoing response in FL |
| Neelapu et al6 | ZUMA-1 | Axi-cel, n = 101 (LBCL) | qPCR | Yes, with grade ≥3 NE | Not with grade ≥3 CRS | Yes, with ORR and with ongoing response |
| Abramson et al7 | TRANSCEND NHL 001 | Liso-cel, n = 245 (LBCL) | qPCR | Yes, with grade ≥3 NE | Yes, with any grade CRS | Yes, with ORR |
| Filosto et al8 | ZUMA-7 | Axi-cel, n = 162 (LBCL) | qPCR | Yes, with grade ≥3 NE | Yes, with grade ≥3 CRS | Yes, with ORR but not with ongoing response |
| Good et al9 | Standard of care | Axi-cel, n = 32 (LBCL) | Flow cytometry and qPCR | Yes, with grade ≥2 ICANS | Yes, with grade 2 CRS | Not with ORR or with ongoing response |
| Blumenberg et al10 | Standard of care | Axi-cel, n = 60 (LBCL); tisa-cel, n = 58 (LBCL) | Flow cytometry | Not assessed | Not assessed | Yes, with PFS and with OS |
Liso-cel, lisocabtagene maraleucel; MZL, marginal zone lymphoma; NE, neurological events; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; qPCR, quantitative polymerase chain reaction; tisa-cel, tisagenlecleucel.